Levothyroxine Tablet Recall Hits Patients Nationwide

The U.S. Food and Drug Administration has issued a Class II nationwide recall of levothyroxine sodium tablets marketed by Major Pharmaceuticals. The recall, announced on July 13 2026, covers 12 product lines across seven dosage strengths (25 mcg to 150 mcg) and specific lot numbers that were found to be subpotent, delivering less hormone than labeled. Affected batches were distributed from Indianapolis and through Cardinal Health.

Patients are advised not to stop taking the medication without medical guidance. They should verify the National Drug Code and lot numbers on their blister packs against the FDA list and contact their pharmacist or physician if they have the recalled product. The FDA notes that exposure is unlikely to cause serious or permanent harm, but subpotent dosing can worsen hypothyroid symptoms such as fatigue, weight gain, cold intolerance, and brain fog.